Our Computational-to-Wet-Lab Approach

Section 1: Dry Lab (Phase I — Complete)

Our discovery engine begins entirely in silico. Using molecular docking, structural bioinformatics, and computational screening, we identify and optimize lead candidates before a single wet experiment is run. This phase has been fully completed for all lead programs.

What we do:

• Target identification & prioritization
• Molecular docking & virtual screening
• ADMET prediction & toxicity filtering
• Lead optimization & patent landscaping

Section 2: Wet Lab (Phase II — In Progress)

Validated computational hits are advanced to in vitro and in vivo experimental confirmation. Our team operates from a proprietary P2-level laboratory facility, ensuring IP security, rapid iteration, and cost efficiency.

What we do:

• In vitro cell-based assays
• In vivo efficacy studies (PDX / syngeneic models)
• PK/PD profiling
• Safety & tolerability assessment

Section 3: CDMO & IND (Phase III — Initiated)

Concurrent with wet-lab execution, we are engaging CDMO partners for process development, scale-up, and CMC. Intellectual property filings are underway to secure global protection for our lead molecules and targets.

What we do:

• CDMO partner selection & tech transfer
• Process development & scale-up
• IP filing (composition of matter, method of use)
• Regulatory strategy & IND preparation